Home › Uterine Cancer › Missouri › St. Louis
Uterine Cancer clinical trials in St. Louis, MO
4 studies for Uterine Cancer are looking for participants at sites in and around St. Louis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, St Louis
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
RecruitingObservational study
- Washington University School of Medicine, St Louis
Investigations of Reproductive Cancers in Women
RecruitingObservational study
- Washington University School of Medicine, St Louis
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
RecruitingPhase 1
- Washington University School of Medicine, St Louis
About Uterine Cancer
Uterine cancer is a cancer that forms in tissues of the uterus. It is more likely to happen after menopause. There are things you can do that may help lower your risk.
More about Uterine Cancer on MedlinePlus
Uterine Cancer trials in other cities
- Houston, TX8 studies
- New York City, NY6 studies
- Columbus, OH6 studies
- Boston, MA5 studies
- Philadelphia, PA5 studies
- Miami, FL5 studies
- Austin, TX5 studies
- West Palm Beach, FL4 studies
- Pittsburgh, PA4 studies
- Chicago, IL4 studies
- Orlando, FL4 studies
- Providence, RI4 studies
Other studies in St. Louis
- Non-Small Cell Lung Cancer73 studies
- Breast Cancer64 studies
- Metastatic Cancer54 studies
- Colorectal Cancer50 studies
- Cancer (all types)46 studies
- Prostate Cancer46 studies
- Lung Cancer39 studies
- Ovarian Cancer38 studies
- Pancreatic Cancer33 studies
- Endometrial Cancer29 studies
- Head and Neck Squamous Cell Carcinoma28 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.